Bli medlem
Bli medlem

Du är här

2020-01-24

RhoVac: BioStock: RhoVac appoints new Chief Development Officer

Rhovac's drug candidate, RV001, is being developed with the goal of
targeting and destroying cancer cells with the potential to
metastasise and a crucial phase IIb study is currently underway.
With RhoVac's Chief Operating Officer (COO), Anders Ljungqvist,
approaching retirement, some managerial re-organisation is taking
place at the company, and, in January, Steffen Wad Jørgensen has
joined RhoVac as Chief Development Officer (CDO). BioStock met with
Steffen to learn more about him and his new role within RhoVac.

Läs hela artikeln och intervjun på biostock.se:
https://www.biostock.se/2020/01/rhovac-appoints-new-chief-development-of...

Detta är ett pressmeddelande från BioStock - Connecting Innovation &
Capital. https://www.biostock.se

-----------------------------------------------------------
https://news.cision.com/se/rhovac/r/biostock-rhovac-appoints-new-chief-d...

Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.